Retatrutide ZPHC — 40 mg (5 vials × 8 mg)

Retatrutide — dual GLP-1 / GIP receptor agonist
5 lyophilised vials × 8 mg (total 40 mg)

• Dual-incretin synergy: simultaneous GLP-1 & GIP activation delivers superior appetite suppression, enhanced insulin sensitivity and rapid fat-loss.
• Once-weekly research dosing: long half-life allows a single sub-Q injection per week.
• Reconstitution: add 2 ml bacteriostatic water → 4 mg/ml; swirl gently, avoid foaming. Store 2–8 °C.
• Titration guide (research): Week 1-4 ➜ 0.5 mg • Week 5-8 ➜ 1 mg • escalate to 2.5 mg weekly if well-tolerated. Increase gradually to minimise GI effects.
• Pharma-grade QC: ≥ 99 % purity, endotoxin < 0.03 EU/mg; each box bears a scratch-code for authenticity.
• Cold-chain packed • tamper-evident vials • discreet, tracked worldwide delivery.